FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988632947> ?p ?o ?g. }

• W2988632947 abstract "The Norwegian Health Services Research Centre was during the spring 2004 asked by the Directorate for Health and Social Affairs to make an evaluation of the effect of oseltamivir (Tamiflu®) for the prevention and treatment of influenza during an influenza pandemic. A group of experts with experience in the field was constituted in May 2004 to assist the Norwegian Health Services Research Centre with this report.BackgroundInfluenza pandemics are sudden and unpredictable, yet inevitable, events. They have caused several global health emergencies during the last century. A pandemic breaks out when a new subtype of influenza virus A arises to which there is little or no immunity in the population. A pandemic most probably will cause greater morbidity and mortality than annual winter outbreaks.Vaccination is the principal means to combat the impact of influenza. An emerging pandemic virus will create a surge in worldwide vaccine demand, and new approaches to immunisation strategies may be needed to ensure optimum protection of unprimed individuals when vaccine supply is limited.A new class of antiviral agents has been developed that specifically inhibits influenza virus neuraminidase, an enzyme essential for viral replication. Oseltamivir is a potent and specific inhibitor of the neuraminidase enzyme of influenza virus types A and B. Oseltamivir is licensed in Norway for the treatment of influenza in adults and children aged one year or older. The drug is also licensed for prophylaxis of influenza in adults and adolescents 13 years or older.ObjectivesThe objective of this study was to assess the effects of oseltamivir (TamifluR) in the prevention and treatment of influenza and to evaluate the cost-effectiveness of oseltamivir, with special reference to an influenza pandemic.Literature SearchRelevant databases that were searched were The Cochrane Library, Database of Abstracts of Reviews of Effectiveness (DARE), International Network of Agencies of Health Technology Assessment (INAHTA) database, National Guidelines Clearinghouse, Medline and Embase.The literature search includes studies from 1980 to October 2004. 133 abstracts were reviewed. 66 possibly relevant studies were assessed, and 15 studies included in the report. In addition, two sets of guidelines were included.Main results / ConclusionsOseltamivir reduces the duration of illness with 1-2 days in previously healthy adults and children with clinical influenza.Severity of illness was significantly reduced by oseltamivir in previously healthy adults, and the frequency and duration of fever was significantly reduced in previously healthy adults and children.Oseltamivir treatment reduces lower respiratory tract complications, antibiotic use, and hospitalization in both healthy and gat riskh adults (age ≥ 65 years, individuals with underlying chronic respiratory or cardiovascular problems).Oseltamivir reduces the duration of cough, fever, time to resolution of illness and frequency of hospitalization in both previously healthy adults, children and gat riskh adults. The frequencies of secondary complications like bronchitis, sinusitis, otitis media, pneumonia, in addition to antibiotic use, were also reduced in most patients.Use of oseltamivir for prophylaxis for periods of five days to six weeks provides a protective effect of 58-89 % against clinical influenza in healthy adults. Prophylaxis for six weeks in a vaccinated frail, elderly population gave a protective effect of 92 %. Children given postexposure prophylaxis for 10 days achieved a protective effect of 55-80 %.Nausea was reported more often in previously healthy adults given oseltamivir than placebo (4.5-18.0 % versus 2.6-7.4 %), as was also the case for vomiting (3.3-14.1 % versus 3.0-3.4 %). Emesis was reported by 14.3 % and 8,5 % of the children given oseltamivir and placebo respectively. The adverse events were transient and of mild to moderate character. Headache was reported with a higher frequency in the oseltamivir group than in the placebo group in adults gat riskh (8.3 % versus 5.5 %).Oseltamivir-resistant mutants occurred in 5.5-18.0 % of children with clinical influenza and in ≤ 4 % of adults.Use of oseltamivir for prophylaxis for six weeks including the whole Norwegian population will imply a cost of NOK 1 900 million. Treatment with oseltamivir for five days (with a pandemic virus given an attack rate of 40 %) will imply a cost of NOK 180 million." @default.
• W2988632947 created "2019-11-22" @default.
• W2988632947 creator A5013948118 @default.
• W2988632947 creator A5020146332 @default.
• W2988632947 creator A5023913678 @default.
• W2988632947 creator A5025515585 @default.
• W2988632947 creator A5032207090 @default.
• W2988632947 creator A5045150125 @default.
• W2988632947 creator A5061088808 @default.
• W2988632947 creator A5067401723 @default.
• W2988632947 creator A5079736758 @default.
• W2988632947 creator A5085457887 @default.
• W2988632947 creator A5088786029 @default.
• W2988632947 date "2005-01-01" @default.
• W2988632947 modified "2023-09-24" @default.
• W2988632947 title "Effect of Oseltamivir (Tamiflu®) for the Prevention and Treatment of Influenza During an Influenza Pandemic" @default.
• W2988632947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29319948" @default.
• W2988632947 hasPublicationYear "2005" @default.
• W2988632947 type Work @default.
• W2988632947 sameAs 2988632947 @default.
• W2988632947 citedByCount "0" @default.
• W2988632947 crossrefType "journal-article" @default.
• W2988632947 hasAuthorship W2988632947A5013948118 @default.
• W2988632947 hasAuthorship W2988632947A5020146332 @default.
• W2988632947 hasAuthorship W2988632947A5023913678 @default.
• W2988632947 hasAuthorship W2988632947A5025515585 @default.
• W2988632947 hasAuthorship W2988632947A5032207090 @default.
• W2988632947 hasAuthorship W2988632947A5045150125 @default.
• W2988632947 hasAuthorship W2988632947A5061088808 @default.
• W2988632947 hasAuthorship W2988632947A5067401723 @default.
• W2988632947 hasAuthorship W2988632947A5079736758 @default.
• W2988632947 hasAuthorship W2988632947A5085457887 @default.
• W2988632947 hasAuthorship W2988632947A5088786029 @default.
• W2988632947 hasConcept C106192422 @default.
• W2988632947 hasConcept C116675565 @default.
• W2988632947 hasConcept C126322002 @default.
• W2988632947 hasConcept C133239900 @default.
• W2988632947 hasConcept C134164806 @default.
• W2988632947 hasConcept C138885662 @default.
• W2988632947 hasConcept C159047783 @default.
• W2988632947 hasConcept C192805744 @default.
• W2988632947 hasConcept C22070199 @default.
• W2988632947 hasConcept C2522874641 @default.
• W2988632947 hasConcept C2777538117 @default.
• W2988632947 hasConcept C2777546802 @default.
• W2988632947 hasConcept C2779134260 @default.
• W2988632947 hasConcept C2780374985 @default.
• W2988632947 hasConcept C2780689484 @default.
• W2988632947 hasConcept C2781442963 @default.
• W2988632947 hasConcept C2908647359 @default.
• W2988632947 hasConcept C3008058167 @default.
• W2988632947 hasConcept C41895202 @default.
• W2988632947 hasConcept C519248777 @default.
• W2988632947 hasConcept C524204448 @default.
• W2988632947 hasConcept C63428231 @default.
• W2988632947 hasConcept C71924100 @default.
• W2988632947 hasConcept C89623803 @default.
• W2988632947 hasConcept C99454951 @default.
• W2988632947 hasConceptScore W2988632947C106192422 @default.
• W2988632947 hasConceptScore W2988632947C116675565 @default.
• W2988632947 hasConceptScore W2988632947C126322002 @default.
• W2988632947 hasConceptScore W2988632947C133239900 @default.
• W2988632947 hasConceptScore W2988632947C134164806 @default.
• W2988632947 hasConceptScore W2988632947C138885662 @default.
• W2988632947 hasConceptScore W2988632947C159047783 @default.
• W2988632947 hasConceptScore W2988632947C192805744 @default.
• W2988632947 hasConceptScore W2988632947C22070199 @default.
• W2988632947 hasConceptScore W2988632947C2522874641 @default.
• W2988632947 hasConceptScore W2988632947C2777538117 @default.
• W2988632947 hasConceptScore W2988632947C2777546802 @default.
• W2988632947 hasConceptScore W2988632947C2779134260 @default.
• W2988632947 hasConceptScore W2988632947C2780374985 @default.
• W2988632947 hasConceptScore W2988632947C2780689484 @default.
• W2988632947 hasConceptScore W2988632947C2781442963 @default.
• W2988632947 hasConceptScore W2988632947C2908647359 @default.
• W2988632947 hasConceptScore W2988632947C3008058167 @default.
• W2988632947 hasConceptScore W2988632947C41895202 @default.
• W2988632947 hasConceptScore W2988632947C519248777 @default.
• W2988632947 hasConceptScore W2988632947C524204448 @default.
• W2988632947 hasConceptScore W2988632947C63428231 @default.
• W2988632947 hasConceptScore W2988632947C71924100 @default.
• W2988632947 hasConceptScore W2988632947C89623803 @default.
• W2988632947 hasConceptScore W2988632947C99454951 @default.
• W2988632947 hasLocation W29886329471 @default.
• W2988632947 hasOpenAccess W2988632947 @default.
• W2988632947 hasPrimaryLocation W29886329471 @default.
• W2988632947 hasRelatedWork W1141220274 @default.
• W2988632947 hasRelatedWork W1502852025 @default.
• W2988632947 hasRelatedWork W1613504209 @default.
• W2988632947 hasRelatedWork W1845358041 @default.
• W2988632947 hasRelatedWork W1937624053 @default.
• W2988632947 hasRelatedWork W1991551961 @default.
• W2988632947 hasRelatedWork W1993585795 @default.
• W2988632947 hasRelatedWork W2000971063 @default.
• W2988632947 hasRelatedWork W2010349160 @default.
• W2988632947 hasRelatedWork W2095981561 @default.
• W2988632947 hasRelatedWork W2103520485 @default.
• W2988632947 hasRelatedWork W2117226770 @default.
• W2988632947 hasRelatedWork W2155379386 @default.
• W2988632947 hasRelatedWork W2325763773 @default.

• next